REHANA GLOD: Open Payments
NPI 1013273820 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$613 in 22 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $141 · 2025 $613
Food & beverage: $613
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $161 |
| Lilly USA, LLC | 3 | $142 |
| Novo Nordisk Inc | 3 | $53 |
| ABBVIE INC. | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| KYOWA KIRIN, INC. | 1 | $24 |
| Boston Scientific Corporation | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
Products named: AIRSUPRA, ZEPBOUND, Ozempic, QULIPTA, MOUNJARO, UPTRAVI, CRYSVITA, General - Pain Management.
Industry payments across VA — which companies pay providers there.
